Ascidian Therapeutics Completes ACDN-01 Dose Escalation in STELLAR Phase 1/2 Trial for Stargardt Disease

Key Takeaways

• Ascidian Therapeutics successfully completed the adult dose escalation portion of its STELLAR Phase 1/2 trial for ACDN-01 in Stargardt disease
• The STELLAR trial is expanding to include pediatric patients, broadening the potential treatment population for this rare genetic eye disease
• A new STARPATH prescreening study is now open to streamline enrollment of both adults and children into future ACDN-01 clinical trials

---

Ascidian Therapeutics, a Boston-based biotechnology company focused on RNA rewriting therapies, announced on May 4, 2026, the successful completion of the adult dose escalation phase of its STELLAR Phase 1/2 clinical trial evaluating ACDN-01 for Stargardt disease treatment.

Trial Expansion and New Enrollment Opportunities

The STELLAR trial will now begin enrolling pediatric subjects, marking a significant expansion of the study population. This development is particularly important for Stargardt disease, a rare inherited retinal disorder that often manifests in childhood and adolescence, causing progressive vision loss.

Concurrently, Ascidian has launched the STARPATH prescreening study, designed to identify and prepare both adult and pediatric patients with Stargardt disease for potential enrollment in future ACDN-01 clinical trials. This prescreening approach aims to accelerate patient recruitment and streamline the clinical development process.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

About ACDN-01 and Stargardt Disease

ACDN-01 represents Ascidian’s innovative RNA rewriting technology platform, which seeks to address genetic diseases at the molecular level. Stargardt disease, the most common form of inherited juvenile macular degeneration, affects approximately 1 in 8,000 to 10,000 individuals worldwide.

The condition is caused by mutations in the ABCA4 gene, leading to the accumulation of toxic byproducts in retinal cells and progressive central vision loss. Currently, no approved treatments exist for Stargardt disease, making ACDN-01’s development particularly significant for patients and families affected by this condition.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Future Outlook

The completion of dose escalation represents a critical milestone in ACDN-01’s development, demonstrating the therapy’s safety profile in adult patients. The expansion to pediatric populations could potentially address the disease at earlier stages, when intervention might be most beneficial.

Ascidian’s RNA rewriting approach differentiates it from traditional gene therapy methods, potentially offering advantages in terms of delivery and therapeutic precision. The company’s progress in this rare disease indication could validate its broader platform technology for other genetic disorders.

---

Frequently Asked Questions

What does completing dose escalation mean for Stargardt disease patients?

Completing dose escalation indicates that ACDN-01 has demonstrated an acceptable safety profile in adult patients at various dose levels, allowing the trial to proceed to the next phase and expand to include children, who are often most affected by Stargardt disease.

When will ACDN-01 be available as a treatment for Stargardt disease?

ACDN-01 is still in Phase 1/2 clinical trials, meaning it will likely be several years before potential approval. Patients can participate in the ongoing STELLAR trial or the new STARPATH prescreening study to access the experimental treatment.

How does ACDN-01’s RNA rewriting approach differ from other Stargardt treatments?

ACDN-01 uses RNA rewriting technology to potentially correct genetic defects at the molecular level, which differs from traditional approaches. Currently, there are no approved treatments for Stargardt disease, making ACDN-01 a potentially first-in-class therapy.

Related coverage

• Orion Pharma's ODM-212 Shows Favorable Safety in Phase 1/2 TEADES Trial for Advanced Solid Tumours
• Risen Pharma Initiates Phase 2 Trial for RP902 in Alzheimer's
• GlycoNex Secures PMDA Approval for GNX1021 Phase I Trial